Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice

Biochemical and Biophysical Research Communications

Volumn 355, Issue 4, 2007, Pages 1075-1080

  Hernandez, Melba ^a   Wright, Samuel D ^a   Cai, Tian Quan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Animal model; CETP; HDL; Niacin; Transgenic mice

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL ESTER TRANSFER PROTEIN; DNA FRAGMENT; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; GENE EXPRESSION; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE;

ANIMALS; APOLIPOPROTEIN B-100; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; HUMANS; MALE; MICE; MICE, TRANSGENIC; NIACIN;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 33847772179     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.02.079     Document Type: Article

References (20)

1. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258 (2005) 94-114
2. McCormack P.L., and Keating G.M. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs. 65 (2005) 2719-2740
3. Carlson L.A. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med. Scand. 173 (1973) 719-722
4. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., and Offermanns S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9 (2003) 352-355
5. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eilert M., Ignar D.M., Murdock P.R., Steplewski K., Green A., Brown A.J., Dowell S.J., Szekeres P.G., Hassall D.G., Marshall F.H., Wilson S., and Pike N.B. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278 (2003) 9869-9874
6. Soga T., Kamohara M., Takasaki J., Matsumoto S., Saito T., Ohishi T., Hiyama H., Matsuo A., Matsushime H., and Furuichi K. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. 303 (2003) 364-369
7. Schaub A., Futterer A., and Pfeffer K. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur. J. Immunol. 31 (2001) 3714-3725
8. Cayen M.N., Kallai-Sanfacon M.A., Dubuc J., Greselin E., and Dvornik D. Evaluation of the lipid-lowering activity of AY-25,712 in rats. Atherosclerosis 45 (1982) 267-279
9. Alton C., Kowalski C., Mallon J., and Marschhaus C. Observations on the cholesterol-lowering mechanism of nicotinic acid and nicotinyl alcohol tartrate. J. Atheroscler. Res. 8 (1968) 265-276
10. Krause B.R., and Princen H.M. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?. Atherosclerosis 140 (1998) 15-24
11. Parwaresch M.R., Haacke H., and Mader C. Efficacy of hypolipidemic treatment in inhibition of experimental atherosclerosis: the effect of nicotinic acid and related compounds. Atherosclerosis 31 (1978) 395-401
12. Tall A.R. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34 (1993) 1255-1274
13. Barter P.J., Brewer Jr. H.B., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 160-167
14. Agellon L.B., Walsh A., Hayek T., Moulin P., Jiang X.C., Shelanski S.A., Breslow J.L., and Tall A.R. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266 (1991) 10796-10801
15. Linton M.F., Farese Jr. R.V., Chiesa G., Grass D.S., Chin P., Hammer R.E., Hobbs H.H., and Young S.G. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92 (1993) 3029-3037
16. Grass D.S., Saini U., Felkner R.H., Wallace R.E., Lago W.J., Young S.G., and Swanson M.E. Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans. J. Lipid Res. 36 (1995) 1082-1091
17. Sniderman A.D., and Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler. Thromb. 13 (1993) 629-636
18. Lewis G.F. Fatty acid regulation of very low density lipoprotein production. Curr. Opin. Lipidol. 8 (1997) 146-153
19. Haemmerle G., Zimmermann R., Strauss J.G., Kratky D., Riederer M., Knipping G., and Zechner R. Hormone-sensitive lipase deficiency in mice changes the plasma lipid profile by affecting the tissue-specific expression pattern of lipoprotein lipase in adipose tissue and muscle. J. Biol. Chem. 277 (2002) 2946-2952
20. Tall A.R. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 86 (1990) 379-384